Clinical Trials Logo

Anti-PD-1 Antibody Resistant clinical trials

View clinical trials related to Anti-PD-1 Antibody Resistant.

Filter by:
  • None
  • Page 1

NCT ID: NCT04514081 Recruiting - Hodgkin Lymphoma Clinical Trials

The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.

Start date: August 1, 2020
Phase: Phase 2
Study type: Interventional

This open-label, randomized, two-arm, phase 2 study has the primary objective of comparing the ORR obtained with Chidamide+Decitabine+Camrelizumab against that obtained with Decitabine+Camrelizumab in patients with Hodgkin Lymphoma who were confirmed resistant to Anti-PD-1 antibody therapy.